✦ LIBER ✦

Combination chemotherapy with mitomycin, vinblastine and cisplatinum for advanced non small cell lung cancer (NSCLC)

✍ Scribed by Gaafar, R.M.; Hamza, M.R.; Zikri, Z.K.; El-Attar, I.; Abdel-Moneim, D.; Khaled, H.M.; Gad El-Mawla, N.

Book ID: 122880632
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 144 KB
Volume: 11
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(94)94261-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitomycin C, vinblastine and cisplatin c

Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer

✍ Fumio Nomura; Kaoru Shimokata; Hiroshi Saito; Shuzo Sakai; Atsushi Watanabe; Hid 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 277 KB

Mitomycin C, vinblastine and cisplatin c

Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 323 KB

Chemotherapy for advanced non-small cell

Chemotherapy for advanced non-small cell lung cancer (NSCLC)

✍ Manegold, Christian 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Carboplatin, vinblastin and mitomycin (C

Carboplatin, vinblastin and mitomycin (CMV) in advanced and disseminated non small cell lung cancer (NSCLC)

✍ Souquet, P.J.; Fournel, P.; Glot, 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Mitomycin C, Vinblastine and Carboplatin

Mitomycin C, Vinblastine and Carboplatin: Effective Outpatient Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)

✍ R.K. Gregory; I.E. Smith; A. Norton; S. Ashley; M.E.R. O'Brien 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Combination chemotherapy with mitomycin-

Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer

✍ Niell, Harvey B. ;Griffin, John P. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

The drug combination of mitomycin-C, cisplatin, and vinblastine was administered to 30 patients with stage III non-small-cell lung cancer. All patients had a performance status of 50% or greater, had evaluable disease, and had not received previous chemotherapy. The overall response rate was 37% wit